Capital One National Association Has Trimmed Its Holding in Johnson & Johnson (JNJ) by $8.00 Million

September 8, 2018 - By Catherine Diaz

Johnson & Johnson (NYSE:JNJ) LogoInvestors sentiment increased to 0.93 in 2018 Q1. Its up 0.06, from 0.87 in 2017Q4. It is positive, as 63 investors sold JNJ shares while 831 reduced holdings. 111 funds opened positions while 720 raised stakes. 1.71 billion shares or 0.80% less from 1.72 billion shares in 2017Q4 were reported. Eqis Mngmt stated it has 25,364 shares. Cutler Investment Counsel Lc owns 76,331 shares for 1.91% of their portfolio. Financial Mgmt Professionals invested in 703 shares or 0.05% of the stock. Brick & Kyle Associates accumulated 23,336 shares. Fmr Lc, a Massachusetts-based fund reported 20.50 million shares. Credit Agricole S A reported 43,235 shares stake. Jp Marvel Invest Advisors Limited Liability Company holds 73,621 shares or 2.91% of its portfolio. The Michigan-based Arcadia Invest Management Corporation Mi has invested 0.18% in Johnson & Johnson (NYSE:JNJ). Jag Management Limited Liability Company holds 14,879 shares. First Bancorp Sioux Falls holds 3.02% or 6,650 shares. Connors Investor Inc invested in 0.15% or 7,802 shares. Macnealy Hoover Investment Mgmt has 3.9% invested in Johnson & Johnson (NYSE:JNJ). Saturna holds 2.52% or 617,978 shares. Puzo Michael J owns 90,670 shares. Snow Cap LP holds 0.02% in Johnson & Johnson (NYSE:JNJ) or 3,215 shares.

Since August 27, 2018, it had 0 buys, and 1 insider sale for $3.91 million activity.

Capital One National Association decreased its stake in Johnson & Johnson (JNJ) by 50.57% based on its latest 2018Q1 regulatory filing with the SEC. Capital One National Association sold 62,535 shares as the company’s stock declined 8.03% with the market. The institutional investor held 61,124 shares of the major pharmaceuticals company at the end of 2018Q1, valued at $7.83M, down from 123,659 at the end of the previous reported quarter. Capital One National Association who had been investing in Johnson & Johnson for a number of months, seems to be less bullish one the $368.40B market cap company. The stock increased 0.33% or $0.45 during the last trading session, reaching $137.32. About 6.38 million shares traded or 1.50% up from the average. Johnson & Johnson (NYSE:JNJ) has declined 4.75% since September 8, 2017 and is downtrending. It has underperformed by 17.32% the S&P500.

Capital One National Association, which manages about $1.43B US Long portfolio, upped its stake in Oneok Inc New (NYSE:OKE) by 72,918 shares to 82,514 shares, valued at $4.70 million in 2018Q1, according to the filing. It also increased its holding in Boeing Co (NYSE:BA) by 14,468 shares in the quarter, for a total of 32,081 shares, and has risen its stake in Vanguard Scottsdale Fds (VGIT).

Analysts await Johnson & Johnson (NYSE:JNJ) to report earnings on October, 16. They expect $2.03 earnings per share, up 6.84 % or $0.13 from last year’s $1.9 per share. JNJ’s profit will be $5.45 billion for 16.91 P/E if the $2.03 EPS becomes a reality. After $2.10 actual earnings per share reported by Johnson & Johnson for the previous quarter, Wall Street now forecasts -3.33 % negative EPS growth.

More notable recent Johnson & Johnson (NYSE:JNJ) news were published by: Seekingalpha.com which released: “When Is The Right Time To Take Profit?” on September 07, 2018, also Seekingalpha.com with their article: “Trump Insurance For Johnson & Johnson” published on August 17, 2018, Seekingalpha.com published: “Johnson & Johnson (JNJ) CEO Alex Gorsky Presents at 2018 Wells Fargo 13th Annual Healthcare Conference …” on September 06, 2018. More interesting news about Johnson & Johnson (NYSE:JNJ) were released by: Seekingalpha.com and their article: “Dividend Champion Spotlight: Johnson & Johnson” published on September 02, 2018 as well as Seekingalpha.com‘s news article titled: “Breakout Alert: Buy Johnson & Johnson” with publication date: August 20, 2018.

Johnson & Johnson (NYSE:JNJ) Ratings Coverage

Among 9 analysts covering Johnson & Johnson (NYSE:JNJ), 5 have Buy rating, 0 Sell and 4 Hold. Therefore 56% are positive. Johnson & Johnson has $16100 highest and $129 lowest target. $145.86’s average target is 6.22% above currents $137.32 stock price. Johnson & Johnson had 13 analyst reports since March 23, 2018 according to SRatingsIntel. The rating was maintained by Jefferies with “Buy” on Friday, April 13. The rating was maintained by Stifel Nicolaus on Wednesday, April 18 with “Hold”. The rating was maintained by Deutsche Bank with “Buy” on Wednesday, April 18. The company was upgraded on Thursday, April 12 by Credit Suisse. The rating was maintained by Credit Suisse with “Outperform” on Friday, April 20. The company was maintained on Friday, March 23 by Jefferies. Leerink Swann maintained the shares of JNJ in report on Wednesday, April 18 with “Buy” rating. As per Thursday, July 12, the company rating was upgraded by Goldman Sachs. Wells Fargo maintained the stock with “Buy” rating in Wednesday, April 18 report. Leerink Swann maintained the shares of JNJ in report on Thursday, May 17 with “Buy” rating.

Johnson & Johnson (NYSE:JNJ) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.